NCT05817890View on ClinicalTrials.gov

Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

May 22, 2024

Conditions
Healthy
Interventions
DRUG

Fadraciclib

Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\]-CYC065 Following a Single Oral Dose in Healthy Male Subjects

Trial Locations (1)

53704

Labcorp Clinical Research Unit, Madison

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT05817890 - Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter